Healthcare Contrast Media Agent Market to reach 9.8% CAGR By | Page 5

Contrast Media / Contrast Agent Market to
reach 9.8% CAGR By 2030
Increasing number of approvals
Over the years market players in the contrast media/contrast agent are focusing on getting
approval from regulatory bodies. For instance in 2017, FDA approved new patient Medication
Guides for all gadolinium-based contrast agents (GBCA). Similarly in 2016, Bracco Diagnostics Inc.
received US FDA approval for Contrast Enhanced Ultrasonography of the Liver. Moreover in
2014, GE Healthcare received approval from Norwegian Medicines Agency for Sonazoid (powder
and solvent for dispersion for injection) for liver lesions.
Side Effects, Allergic Reactions, and Adverse Effects Associated With Contrast Agents
Many patient and physician have recorded adverse effect related to contrast media/contrast
agent. According to a paper published in Journal of Radiology it was observed that varied levels
of residual gadolinium were accumulated in the brain. This may be toxic to patients
administrated by gadolinium based contrast.
Request For Report Methodology@ https://www.marketindustryreports.com/free-customization/71